Current Concepts

Urinary Complications of Cyclophosphamide Therapy Etiology, Prevention, and Management

Authors: FREDERICK A. KLEIN MD, M. J. VERNON SMITH MD, PhD

Abstract

ABSTRACTCyclophosphamide is a well established cytotoxic drug used in the treatment of lymphoproliferative disorders, certain solid tumors, and nonneoplastic disorders such as the nephrotic syndrome, systemic lupus erythematosus, and rheumatoid arthritis. Hemorrhagic cystitis can be a complication of this drug in from 2% to 40% of patients so treated. At times, the hemorrhage may be severe, protracted, and life-threatening. Cyclophosphamide therapy has also been implicated as the causative agent in 32 cases of carcinoma of the bladder and three cases of carcinoma of the renal pelvis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References